Short Interest in IceCure Medical Ltd (NASDAQ:ICCM) Expands By 26.9%

IceCure Medical Ltd (NASDAQ:ICCM) was the target of a large increase in short interest in July. As of July 15th, there was short interest totalling 196,500 shares, an increase of 26.9% from the June 30th total of 154,900 shares. Currently, 0.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 264,000 shares, the days-to-cover ratio is currently 0.7 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of IceCure Medical in a research note on Tuesday, July 2nd.

IceCure Medical Trading Up 0.1 %

NASDAQ ICCM traded up $0.00 on Tuesday, reaching $0.74. The company had a trading volume of 87,213 shares, compared to its average volume of 482,598. The stock’s 50 day moving average is $0.82 and its 200-day moving average is $1.11. The stock has a market cap of $33.70 million, a price-to-earnings ratio of -2.24 and a beta of 0.57. The company has a quick ratio of 2.88, a current ratio of 3.39 and a debt-to-equity ratio of 0.03. IceCure Medical has a 52 week low of $0.52 and a 52 week high of $1.57.

IceCure Medical (NASDAQ:ICCM) last posted its quarterly earnings data on Tuesday, May 28th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). IceCure Medical had a negative return on equity of 101.66% and a negative net margin of 444.30%. The business had revenue of $0.74 million during the quarter, compared to the consensus estimate of $0.80 million. During the same period last year, the company earned ($0.08) earnings per share. Equities analysts predict that IceCure Medical will post -0.28 earnings per share for the current year.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.